Patrick Chi-Chung Ma, MD, MSc

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Lung Neoplasms 76%
3. Hepatocyte Growth Factor 73%
4. Small Cell Lung Carcinoma 70%
5. Neoplasms 60%
6. ErbB Receptors 60%
7. Mutation 48%
8. Erlotinib Hydrochloride 39%
9. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) 36%
10. Protein-Tyrosine Kinases 34%
11. Adenocarcinoma of Lung 34%
12. Therapeutics 32%
13. Receptor Protein-Tyrosine Kinases 29%
14. Neoplasm Metastasis 23%
15. Immunotherapy 21%
16. Proto-Oncogene Proteins c-met 21%
17. ARQ 197 18%
18. Carcinogenesis 17%
19. Cell Movement 17%
20. Drug Therapy 16%
21. Ligands 16%
22. Exons 15%
23. Signal Transduction 15%
24. Tumor Biomarkers 15%
25. Biomarkers 14%
26. Phosphotransferases 14%
27. Cell Line 13%
28. Anaplastic Lymphoma Kinase 13%
29. Fluorescence In Situ Hybridization 12%
30. STAT3 Transcription Factor 11%
31. Gefitinib 11%
32. Proteins 11%
33. Survival 11%
34. Long Noncoding RNA 11%
35. Lung 11%
36. ARRY-470 10%
37. Growth 10%
38. Crizotinib 10%
39. Alternative Splicing 10%
40. glembatumumab vedotin 10%
41. 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one 10%
42. ABT751 10%
43. rebeccamycin 9%
44. RRx-001 9%
45. Phosphatidylinositol 3-Kinases 9%
46. onartuzumab 9%
47. Cell Proliferation 9%
48. Immunohistochemistry 8%
49. Disease Progression 8%
50. Gene Amplification 8%